Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate
Arcturus Therapeutics (Nasdaq: ARCT) has announced the appointment of Dr. Moncef Slaoui as Chair Designate. Dr. Slaoui, who has been serving on the Company's Board of Directors since June 2024, brings extensive experience in the pharmaceutical and biotechnology industry. The company, which focuses on commercial messenger RNA medicines for infectious disease vaccines and rare diseases affecting liver and respiratory systems, is entering what it describes as a transformative year with multiple key data readouts expected across its pipeline.
Arcturus Therapeutics (Nasdaq: ARCT) ha annunciato la nomina del Dr. Moncef Slaoui come Presidente Designato. Il Dr. Slaoui, che fa parte del Consiglio di Amministrazione della Società da giugno 2024, porta un'esperienza vasta nell'industria farmaceutica e biotecnologica. L'azienda, che si concentra su medicinali a base di RNA messaggero commerciali per vaccini contro malattie infettive e malattie rare che colpiscono il fegato e i sistemi respiratori, sta entrando in quello che descrive come un anno trasformativo con molteplici letture di dati chiave attese lungo il suo pipeline.
Arcturus Therapeutics (Nasdaq: ARCT) ha anunciado el nombramiento del Dr. Moncef Slaoui como Presidente Designado. El Dr. Slaoui, quien ha estado sirviendo en la Junta Directiva de la compañía desde junio de 2024, trae una amplia experiencia en la industria farmacéutica y biotecnológica. La empresa, que se enfoca en medicamentos comerciales de ARN mensajero para vacunas contra enfermedades infecciosas y enfermedades raras que afectan los sistemas hepático y respiratorio, está entrando en lo que describe como un año transformador con múltiples lecturas clave de datos esperadas en su pipeline.
Arcturus Therapeutics (Nasdaq: ARCT)는 Dr. Moncef Slaoui를 의장 지명자로 임명했다고 발표했습니다. Slaoui 박사는 2024년 6월부터 회사 이사회에서 활동하고 있으며, 제약 및 생명공학 산업에서 폭넓은 경험을 가지고 있습니다. 감염병 백신과 간 및 호흡기계를 영향을 미치는 희귀 질환을 위한 상업적 메신저 RNA 약물에 초점을 맞춘 이 회사는 여러 주요 데이터 공개가 예상되는 변혁의 해에 들어서고 있다고 설명하고 있습니다.
Arcturus Therapeutics (Nasdaq: ARCT) a annoncé la nomination du Dr. Moncef Slaoui en tant que Président désigné. Le Dr Slaoui, qui fait partie du Conseil d'Administration de l'entreprise depuis juin 2024, apporte une vaste expérience dans l'industrie pharmaceutique et biotechnologique. L'entreprise, qui se concentre sur des médicaments à ARN messager commerciaux pour les vaccins contre les maladies infectieuses et les maladies rares affectant les systèmes hépatique et respiratoire, entre dans ce qu'elle décrit comme une année transformative avec plusieurs résultats clés de données attendus dans son pipeline.
Arcturus Therapeutics (Nasdaq: ARCT) hat die Ernennung von Dr. Moncef Slaoui zum vorgesehenen Vorsitzenden bekannt gegeben. Dr. Slaoui, der seit Juni 2024 im Vorstand des Unternehmens tätig ist, bringt umfangreiche Erfahrungen aus der Pharma- und Biotechnologiebranche mit. Das Unternehmen, das sich auf kommerzielle Messenger-RNA-Medikamente für Impfstoffe gegen Infektionskrankheiten und seltene Krankheiten, die Leber- und Atemwegssysteme beeinträchtigen, konzentriert, tritt in ein, wie es selbst beschreibt, transformatives Jahr mit mehreren bevorstehenden wichtigen Datenausgaben in seiner Pipeline ein.
- Appointment of industry veteran Dr. Moncef Slaoui as Chair Designate
- Multiple key data readouts expected across pipeline
- Company has validated commercial stage vaccines platform
- None.
“Dr. Moncef Slaoui has a long-proven track record in the pharmaceutical and biotechnology industry, and we are delighted to have him as our Chair Designate,” said Joseph Payne, President & Chief Executive Officer of Arcturus. “We look forward to working with him as we enter a transformative year of advancing our pipeline of therapeutics and vaccines.”
“Arcturus has deep expertise in mRNA delivery for therapeutics and a validated commercial stage vaccines platform,” said Dr. Moncef Slaoui. “I am excited to work with the company during this potentially transformational time with multiple key data readouts across its pipeline.”
About Dr. Moncef Slaoui
Dr. Moncef Slaoui was most recently the Chief Scientific Advisor to Operation Warp Speed. Under his leadership the operation enabled the fastest ever development, manufacturing, and approval of multiple COVID-19 vaccines in less than 11 months after the virus genetic sequence was described. Dr. Slaoui has sat on several biotechnology company boards, including Moderna, Inc. and Lonza Group AG, and he chaired the boards of Galvani, and Vaxcyte, a vaccine development platform company.
Dr. Slaoui spent nearly 30 years at GlaxoSmithKline (GSK) holding leadership positions including as member of the Board of Directors of GSK PLC; Chairman of Pharmaceutical R&D; Chairman Global R&D, Vaccines & Oncology; and Chairman, Global Vaccines. As Chairman of Pharmaceutical R&D, Dr. Slaoui led a redesign of GSK’s R&D structure and culture to improve focus on innovation and productivity. As Chairman of Global Vaccines, Dr. Slaoui was directly involved in GSK's vaccine pipeline, leading to the creation of 14 new vaccines, including Shingrix®, to prevent shingles; Cervarix®, to prevent cervical cancer; Mosquirix, to prevent malaria; Rotarix®, to prevent rotavirus gastroenteritis; and Synflorix, to prevent pneumococcal disease.
In 2016, Dr. Slaoui was recognized as one of Fortune's 50 Greatest World Leaders for his work in under-researched diseases common in the developing world. He served on the Advisory Committee to the Director of the NIH from 2011 to 2016 and has advised the
Dr. Slaoui holds a Ph.D. in Molecular Biology and Immunology from the Université Libre de
About Arcturus
Founded in 2013 and based in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250204663825/en/
Arcturus Therapeutics
Public Relations & Investor Relations
Neda Safarzadeh
VP, Head of IR/PR/Marketing
(858) 900-2682
IR@ArcturusRx.com
Source: Arcturus Therapeutics Holdings Inc.
FAQ
When did Dr. Moncef Slaoui join Arcturus Therapeutics (ARCT) board of directors?
What is Arcturus Therapeutics' (ARCT) main business focus?
What significant developments are expected for Arcturus (ARCT) in the near future?